Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment

Acticor Biotech is progressing with the development of glenzocimab, a drug aimed at addressing cardiovascular emergencies, with a focus on myocardial infarction, particularly ST-Elevation Myocardial Infarction (STEMI). The company reports that 27 patients have been recruited for the phase 2b LIBERATE study, which aims to evaluate glenzocimab's efficacy in reducing the size of myocardial infarctions and minimizing microvascular complications. This study is a partnership with the University of Birmingham, UK, and results are anticipated by Q4 2026.

Additionally, a phase 2 study named GLORIA is being prepared. It will assess glenzocimab's efficiency in angioplasty and aims to enroll 300 STEMI patients. The study will explore various dosages and optimize the drug's administration mode. Recruitment could begin in Q1 2025, contingent upon funding.